Oncology research veterans have launched a clinical research solutions firm TrialNAV which connects industry sponsors, clinical trial sites and cancer subjects.
TrialNAV suite of offerings will provide its clients a comprehensive solution for the recognised challenges in the pharmaceutical and technology industries.
They include site management organisations, clinical research organisations and trial sites within healthcare organisations.
The solutions are intended to enhance enrolment in clinical research and offer improved access to therapy options for cancer patients.
Services of the company are categorised into three business units to offer curated solutions. The units include consulting for industry and HCO research sites, development of technology as well as patient and caregiver support.
TrialNAV offers streamlining and implementation for trial start-up and ongoing operations, sponsor and biospecimen international trial-to-site sourcing and procurement and trial design for industry sponsors.
It creates programme architecture for research sites focusing on efficiency in viability, staffing solutions, portfolio management, digital transformation, decentralised trials and multicentre trial management.
The technology development team of the company offers innovation to develop tools to overcome the hurdles in trial enrolment, including software platforms that can directly empower patients and their caregivers to advocate for their therapy and support requirements.
TrialNAV co-founder and co-CEO Tandy Tipps said: “With the formation of TrialNAV, we are thrilled to harness our combined knowledge in the industry, technology, and cancer centre site operations to offer clinical research sites a wide breadth of solutions to improve their trial operations, create meaningful partnerships, and grow their research programmes.
“In addition, our network of diverse and established research sites provides trial sponsors confidence that the sites they select for their trials are well-positioned to enrol patients and carry out optimised clinical operations – from start-up and enrolment to study closure.”
